Check-Cap is an Israeli-incorporated shell company in transition. Its original business — developing C-Scan, a swallowable X-ray capsule designed to screen for colorectal cancer without bowel preparation or sedation — was discontinued in June 2023 after clinical data failed to meet the threshold to proceed with its U.S. pivotal study. After spending over a decade and accumulating a deficit of $165.9M, Check-Cap shifted to pursuing strategic alternatives. The company is now primarily a vehicle for a pending reverse merger with MBody AI, an AI robotics software company targeting large commercial venues such as hotels, casinos, and convention centers. MBody AI's core product is the AI Orchestrator, a proprietary software platform that integrates and manages fleets of autonomous robots from multiple hardware manufacturers within a single customer environment. MBody AI does not manufacture hardware; it procures third-party robotic equipment and bundles it with its software in a turnkey model that includes deployment, financing, maintenance, and ongoing software subscriptions. Revenue streams include recurring AI platform subscription fees, integration and analytics services, and hardware enablement revenue. The merger was approved by Check-Cap shareholders in November 2025, with MBody AI shareholders expected to own roughly 90% of the combined company post-close. The combined company plans to rename itself MBody AI Ltd. Check-Cap carries a going-concern qualification, and its remediation plan depends on closing the merger and a $30M equity line of credit committed by ARC Group.